Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases

@article{Mazanetz2007UntanglingTH,
  title={Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases},
  author={Michael P. Mazanetz and Peter M. Fischer},
  journal={Nature Reviews Drug Discovery},
  year={2007},
  volume={6},
  pages={464-479}
}
Aggregation of hyperphosphorylated tau is one of the characteristic neuropathological lesions of Alzheimer's disease and other neurodegenerative disorders. Pharmacological modulation of tau hyperphosphorylation might represent a valid and feasible therapeutic strategy for such disorders. Here, we consider recent evidence supporting the validity of the three most relevant kinases affecting tau hyperphosphorylation — GSK3β, CDK5 and ERK2 — as drug targets and describe progress in the design of… CONTINUE READING
Highly Influential
This paper has highly influenced 11 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 144 extracted citations

Stress acts cumulatively to precipitate Alzheimer's disease-like tau pathology and cognitive deficits.

The Journal of neuroscience : the official journal of the Society for Neuroscience • 2011
View 4 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 169 references

An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice.

Proceedings of the National Academy of Sciences of the United States of America • 2006

Crystal structure of human ERK 2 complexed with a pyrazolo [ 3 , 4c ] pyridazine derivative

T. Kinoshita
Bioorg . Med . Chem . Lett . • 2006

Similar Papers

Loading similar papers…